Browse MOAP1

Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF14893 PNMA
Function

Required for death receptor-dependent apoptosis. When associated with RASSF1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation.

> Gene Ontology
 
Biological Process GO:0001836 release of cytochrome c from mitochondria
GO:0001844 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway
GO:0006839 mitochondrial transport
GO:0007006 mitochondrial membrane organization
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0008637 apoptotic mitochondrial changes
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0035794 positive regulation of mitochondrial membrane permeability
GO:0038034 signal transduction in absence of ligand
GO:0046902 regulation of mitochondrial membrane permeability
GO:0051204 protein insertion into mitochondrial membrane
GO:0051205 protein insertion into membrane
GO:0070585 protein localization to mitochondrion
GO:0072655 establishment of protein localization to mitochondrion
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:0090199 regulation of release of cytochrome c from mitochondria
GO:0090200 positive regulation of release of cytochrome c from mitochondria
GO:0090559 regulation of membrane permeability
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097345 mitochondrial outer membrane permeabilization
GO:1902108 regulation of mitochondrial membrane permeability involved in apoptotic process
GO:1902110 positive regulation of mitochondrial membrane permeability involved in apoptotic process
GO:1902686 mitochondrial outer membrane permeabilization involved in programmed cell death
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0005741 mitochondrial outer membrane
GO:0019867 outer membrane
GO:0031968 organelle outer membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MOAP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MOAP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MOAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7710.0108
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4220.477
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.30.831
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.170.00782
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.3890.107
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9010.415
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0960.782
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0230.988
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.240.886
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0560.965
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5140.783
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0060.93
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MOAP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MOAP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MOAP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MOAP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MOAP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MOAP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MOAP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMOAP1
Namemodulator of apoptosis 1
Aliases MAP-1; PNMA4; paraneoplastic Ma antigen family member 4; paraneoplastic antigen Ma4; paraneoplastic antigen ......
Chromosomal Location14q32.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MOAP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.